Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy

NCT07561060 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer

Interventions

DRUG: Tislelizumab
DRUG: Capecitabine
DRUG: Oxaliplatin
DRUG: Capecitabine

Sponsor

Fudan University